SANGUINE CORP. (SGNC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike Ankley who wrote (3003)	7/11/1998 10:52:00 PM
From: Mr. Forthright	Read Replies (1) of 5402

Great research. A lot of it sounds familiar. Doesn't it? <<Yet it is still imperative that a value can be estimated within a reasonable range for practical purposes such as raising capital, negotiating strategic alliances and joint venture agreements, investment decisions, and licensing strategies. Investors need to benchmark the company against other companies, to evaluate whether the market's valuation for biotech companies are efficient or not.>> <<The development life cycle is very long, on average ranging anywhere from 16 to 20 years.>> <<For example, in the drug development and approval process, only one in five thousand compounds that enter preclinical testing make it to human testing, and then only one in five are approved. Of those products which are approved, few biotechnology products which reach the market generate sufficient return to cover their cost.>>

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next